Table 4.
Clinical trials of antidepressant treatment associated epigenetic modifications.
| Study | ClinicalTrials.gov Identifier | Status | Phase | Aims | Intervention | Condition | Publications |
|---|---|---|---|---|---|---|---|
| Paliperidone and lithium in the treatment of suicidality—treatment indication and epigenetic regulation (AFSP) | NCT01134731 | Completed | Phase 4 | To identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment. | Paliperidone and lithium | MDD Suicidality | Not provided |
| Epigenetic regulation of brain-derived neurotrophic factor (BDNF) in major depression | NCT01182103 | Completed | ----- | To detect the associations between BDNF, DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in MDD patients, check the correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and discuss the possible mechanisms of epigenetic regulation of BDNF in Taiwanese MDD patients. | ----- | MDD | Not provided |
| A neuroimaging and epigenetic investigation of antidepressants in depression | NCT00703742 | Completed | ----- | To find out the structural or functional effects of SSRI in MDD; to explore the DNA methylation status in depression; to find special abnormalities in depression secondary to other disease (autoimmune disease like systemic lupus erythematosus). | Escitalopram | Depression secondary to other disease | [128,129] |
| miRNAs, suicide, and ketamine—plasma exosomal microRNAs as novel biomarkers for suicidality and treatment outcome | NCT02418195 | Recruiting participants | Phase 2 | To examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are associated with suicidal behavior and response to ketamine. | ketamine | MDD | Not provided |
| Add-On Study of MSI-195 (S-adenosyl-l-methionine, SAMe) for patients with major depressive disorder (MDD) | NCT01912196 | Ongoing | Phase 2 | To determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD) patients with inadequate response to current antidepressant therapy. | MSI-195 and Placebo | MDD | Not provided |